Saturday, September 17, 2022
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Isatuximab provides a clinically meaningful benefit in overall survival (OS) when added to pomalidomide and low-dose dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (MM), according to researchers.
Read more here.